A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NR improved the six-minute walking distance and treadmill walking time for those with PAD LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II clinical study...
Believes now is the time to move from a linear to a circular economic modelARCO, Italy, June 20, 2024 -- Aquafil SpA (ECNLF:OTCQX - ECNL:IM), based in Arco (TN) Italy and a pioneer of the circular economy, believes now is the time for business leaders to make a...
Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized...
ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to...
I would like to welcome Flow Beverage Corp., a premium and sustainable water company. The ticker symbols are FLOW on the Toronto and FLWBF on the OTCQX. Presenting from the company today is Trent MacDonald, Chief Financial Officer. Flow is one of the fastest-growing...
For this presentation, we welcome Lincoln Educational Services Corporation, which trades on the NASDAQ under the ticker LINC. Joining us from the company is Scott Shaw, President and Chief Executive Officer, to give us an overview of the company. Lincoln Tech is a...
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating...
Judges award Niagen for its "high-quality, unparalleled" healthy aging research LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce that its flagship ingredient,...
Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. LOS ANGELES -...